If you have just been diagnosed, the first thing you may notice is that everyone asks the same questions before they talk about treatment: What stage? Is it hormone positive? HER2? Triple negative? That is because breast cancer stopped being one disease years ago. The medicines that work brilliantly for one type do nothing for another, and the pace of new approvals has never been faster. This guide walks through what is approved for each stage and type, what changed in the last year, and what researchers are testing now.
Looking for treatment options for Breast Cancer?
Browse open clinical trials near you! We'll handle the follow-up.
First, the three questions that decide everything
Your pathology report answers three questions, and they matter more than the size of the tumor.
Is it hormone receptor positive? About 7 in 10 breast cancers grow in response to estrogen or progesterone. Blocking those hormones, with pills taken for 5 to 10 years, is the backbone of treatment for this group.
Is it HER2 positive? About 15 to 20 percent of breast cancers make too much of a growth protein called HER2. Twenty five years ago this was the most aggressive type. Today it is one of the most treatable, because antibodies that target HER2 changed everything.
Is it triple negative? About 10 to 15 percent have none of those targets. For decades that meant chemotherapy alone. Immunotherapy and a new class of drugs called antibody drug conjugates have started to change that.
Then comes stage: 0 to IV, based on size, lymph nodes, and spread. Most breast cancer, about two thirds, is found while still confined to the breast, where five year survival exceeds 99 percent. About 1 in 20 is metastatic at diagnosis. For the full staging picture, our breast cancer page walks through each stage.
What is approved for early stage breast cancer
Surgery and radiation. Either lumpectomy (removing the tumor) with radiation, or mastectomy. Large trials showed decades ago that for most early cancers, lumpectomy plus radiation is as effective as removing the whole breast. Lymph node surgery has become far less extensive over time as trials showed less was safe.
Chemotherapy, but not for everyone. Genomic tests like Oncotype DX analyze the tumor's genes to predict who actually benefits from chemotherapy. A landmark trial showed that most women with hormone positive, node negative disease and a low or intermediate score can safely skip it. Fewer people get chemo today than 15 years ago, and outcomes are better.
Hormone therapy for hormone positive disease. Tamoxifen or aromatase inhibitors for 5 to 10 years cut recurrence substantially. For higher risk early disease, adding a CDK4/6 inhibitor pill (ribociclib, brand name Kisqali, or abemaciclib, Verzenio) for two to three years lowers recurrence further. Staying on these pills is hard because of side effects, which is why some trials now study how to help people stick with them.
HER2 targeted therapy for HER2 positive disease. Trastuzumab (Herceptin), often with pertuzumab, given with chemotherapy before or after surgery. On May 15, 2026 the FDA approved trastuzumab deruxtecan (Enhertu) for early HER2 positive disease in two settings: before surgery for high risk stage II and III disease, and after surgery for people who still have invasive disease remaining after neoadjuvant treatment with trastuzumab and a taxane.
Immunotherapy for triple negative disease. Pembrolizumab (Keytruda) with chemotherapy before surgery, continued afterward, is now standard for higher risk early triple negative cancer, the first time immunotherapy reached early breast cancer.
What is approved for metastatic breast cancer
Metastatic breast cancer is not curable today, but it is treatable for years, and this is where most new approvals land.
Hormone positive. First treatment is usually hormone therapy plus a CDK4/6 inhibitor. When that stops working, the choice depends on mutations found by a blood test: alpelisib or inavolisib (Itovebi, approved 2024) for PIK3CA mutations, capivasertib (Truqap) for PIK3CA, AKT1, or PTEN changes,and elacestrant (Orserdu) or imlunestrant (Inluriyo, approved September 2025) for ESR1 mutations, which develop as resistance to standard hormone therapy. In September 2026 the FDA also approved imlunestrant combined with abemaciclib for the same group, after a trial in which the combination doubled the time before the cancer progressed compared with imlunestrant alone.
HER2 positive. On December 15, 2025, the FDA approved trastuzumab deruxtecan plus pertuzumab as first line treatment, the first new frontline regimen for HER2 positive metastatic disease in more than a decade. In the DESTINY-Breast09 trial it cut the risk of progression by 44 percent compared with the previous standard, with median time before progression above three years. Trastuzumab deruxtecan also works in "HER2 low" cancers, a category that did not exist until this drug showed it mattered, which brought targeted therapy to roughly half of people previously labeled HER2 negative.
Triple negative. Immunotherapy plus chemotherapy for tumors that express PD-L1, sacituzumab govitecan (Trodelvy) after earlier treatment, and PARP inhibitors for people with inherited BRCA mutations. Datopotamab deruxtecan (Datroway), approved in 2025 for hormone positive disease, is being tested here too.
What researchers are studying now
Getting metastatic drugs to earlier stages. The pattern in breast cancer is that drugs prove themselves in metastatic disease, then move earlier where they can prevent recurrence. A study of inavolisib in early stage breast cancer and a Phase 3 trial of inavolisib with Phesgo in PIK3CA mutated HER2 positive disease both follow that path.
Better hormone blockers. Oral SERDs, pills that degrade the estrogen receptor, aim to work where standard hormone therapy has failed. A Phase 3 trial of giredestrant compares one against current standard in advanced hormone positive disease.
Head to head, and next generation HER2. A trial comparing RO7771950 with tucatinib, an approved drug, in HER2 positive disease, is the kind of direct comparison that tells doctors which option is better, not just whether a drug works.
Vaccines to prevent recurrence. A HER2 vaccine for locally advanced breast cancer and a HER2 peptide vaccine for metastatic disease aim to train the immune system to recognize HER2 so the cancer cannot come back. Early stage research, and one of the field's most watched ideas.
Less treatment, same result. A trial of shorter chemo immunotherapy without anthracycline drugs in early stage disease asks whether people can be spared heart toxic chemotherapy without losing benefit. De escalation trials like this are as important as new drugs.
Finding it earlier, for everyone. A trial comparing screening mammography with and without artificial intelligence assistance tests whether AI catches cancers radiologists miss. And a community navigation study tests whether guiding underserved patients through the system closest he survival gap that Black women, who die of breast cancer at a 38 percent higher rate than white women despite similar incidence, still face.
Why breast cancer research takes time
The good outcome problem. Because most early breast cancer is cured, proving a new treatment lowers recurrence requires thousands of participants followed for five years or more. That is why early stage approvals lag metastatic approvals by years.
The subtype problem. A drug for HER2 positive disease is useless in triple negative. Each subtype, and now each mutation within a subtype, needs its own trials, which multiplies the work and shrinks the pool of eligible participants.
The resistance problem. Metastatic breast cancer evolves. A drug that works for two years stops working as the tumor develops new mutations. Much of current research is about the next line: what to give when the last thing failed, guided by blood tests that track those mutations.
The representation problem. Black women are more likely to get triple negative disease and to die of breast cancer, yet remain underrepresented in the trials that shaped current treatment. Several current studies name diverse enrollment as a goal. Here's why diversity in clinical trials matters so much.
Common myths about breast cancer
"Finding a lump means it is cancer."
Most breast lumps are benign, especially in younger women. Every new lump should be checked, but most are cysts or fibroadenomas.
"A mastectomy is safer than a lumpectomy."
For most early breast cancers, decades of trials show lumpectomy plus radiation gives the same survival as mastectomy. The choice is personal and depends on the tumor, not on one being safer.
"Chemotherapy is always part of treatment."
Fewer women receive chemotherapy today than 15 years ago. Genomic tests identify who benefits, and many people with hormone positive early disease safely skip it.
"Metastatic means months to live."
Not anymore for many people. Five year survival for distant disease has roughly doubled since the 1990s, and people with hormone positive or HER2 positive metastatic disease often live many years on sequential treatments.
How to find a breast cancer clinical trial
AllClinicalTrials.com lists breast cancer studies recruiting across the US, from Phase 3 drug trials to screening, vaccine, and survivorship research. Two examples recruiting right now: the Phase 3 giredestrant trial for people with estrogen receptor positive, HER2 negative advanced breast cancer, and a shorter chemo immunotherapy study for early stage disease that avoids anthracycline drugs.
The application takes about 5 minutes: you answer questions about your subtype, stage, and treatments so far, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Three things to have ready: your receptor status and any mutation results, your stage, and the list of treatments you have had.
Common questions
What is the newest treatment for breast cancer? The most recent major approvals are trastuzumab deruxtecan (Enhertu) plus pertuzumab as first line treatment for HER2 positive metastatic disease in December 2025, and Enhertu for early stage HER2 positive disease in May 2026. For hormone positive disease, imlunestrant (Inluriyo) was approved in September 2025 for ESR1 mutated cancers, and in September 2026 the combination of imlunestrant with abemaciclib was approved for the same group. Oral SERDs and HER2 vaccines are the most watched pipeline areas.
What is the survival rate for breast cancer? Overall five year relative survival is 91 percent and ten year survival is 84 percent. For cancer still confined to the breast it is above 99 percent; for regional spread about 86 percent; for distant metastatic disease about 30 percent, roughly double what it was in the 1990s. These are population figures, not predictions for any individual, and depend heavily on subtype.
Can breast cancer be cured? Early stage breast cancer, stages 0 to III, is frequently cured, though doctors usually say "no evidence of disease" because recurrence can occur years later. Metastatic breast cancer is not curable with current treatment but is often controlled for years.
Do breast cancer trials use placebo? Rarely in place of treatment. In breast cancer trials the comparison group receives the current standard treatment, and a placebo, if used, is added on top of it. Leaving a breast cancer patient untreated would be unethical, and trial designs reflect that. Our guide to placebo controlled trials explains how this works.
See clinical trials for breast cancer recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Breast Cancer Clinical Trials